MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts
Launched by ETH ZURICH · Jul 29, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help people with neuropathy, a condition that causes damage to the nerves and can lead to chronic pain and loss of sensation, especially in the feet. The goal is to use a special insole with pressure sensors that can provide real-time feedback about how someone is walking, combined with Virtual Reality (VR) technology. This system aims to help reduce pain and improve the brain's response to sensory information, potentially leading to better balance and mobility for participants.
To be eligible for the trial, participants must be between 18 and 80 years old, have good vision, and be diagnosed with peripheral neuropathy that causes pain in their lower limbs. There are some exclusions, such as pregnancy or certain medical conditions like epilepsy or unhealed wounds. Participants can expect to engage with the sensory feedback system and undergo brain scans to see how it affects their pain and brain function. This innovative approach seeks to offer hope for improved treatment options for those suffering from neuropathic pain.
Gender
ALL
Eligibility criteria
- for healthy:
- * Inclusion:
- • Age 18-80
- • Visual acuity\>6 on Snellen visual acuity chart
- * Exclusion:
- • Pregnancy
- • Cognitive deficits (Mini Mental State Examination\<23)
- • Cyber-sickness
- • Prior or current psychological diseases
- • Pacemakers
- • Epilepsy
- • Claustrophobia
- • Other MRI contraindications
- • Unhealed fractures
- • Unhealed wounds
- • Cancerous growth in proximity to feet
- • Swollen, infected or inflamed areas on feet or skin eruptions on feet such as phlebitis, thrombophlebitis or varicose veins
- for patients:
- * Inclusion:
- • Age 18-80
- • Visual acuity\>6 on Snellen visual acuity chart
- • Diagnosis of peripheral neuropathy
- • Pain in lower limbs\>=3 cm on VAS scale
- * Exclusion:
- • Pregnancy
- • Relevant comorbidities that would affect the outcomes of the study (by judgement of physicians)
- • Ulcers
- • Cognitive deficits (Mini Mental State Examination\<23)
- • Cyber-sickness
- • Prior or current psychological diseases
- • Pacemakers
- • Epilepsy
- • Claustrophobia
- • Other MRI contraindications
- • Unhealed fractures
- • Unhealed wounds
- • Cancerous growth in proximity to feet
About Eth Zurich
ETH Zurich, a prestigious institution known for its cutting-edge research and innovation, is a leading sponsor of clinical trials focused on advancing medical science and improving patient outcomes. With a strong emphasis on interdisciplinary collaboration, ETH Zurich leverages its expertise in engineering, technology, and life sciences to explore novel therapeutic approaches and enhance healthcare delivery. The institution is committed to adhering to rigorous ethical standards and regulatory compliance, ensuring the integrity and scientific validity of its clinical research initiatives. Through its sponsorship, ETH Zurich aims to contribute significantly to the development of transformative treatments and interventions that address critical healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Stanisa Raspopovic, Prof. Dr.
Principal Investigator
ETH Zurich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials